Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELARIS UF-1: Elagolix for Heavy Menstrual Bleeding in Uterine Fibroids
NCT02654054Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of elagolix in Uterine Fibroids (UF), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants Meeting the Criteria for Responder at Month 6. Started Dec 2015; status: completed.
02
Drugs
elagolix
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT02654054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654054.